Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

W. Tolcher, Anthony; Sznol, Mario; Hu‐Lieskovan, Siwen; P. Papadopoulos, Kyriakos; Patnaik, Amita; Rasco, Drew; Di Gravio, Donna; Huang, Bo; Gambhire, Dhiraj; Chen, Ying; D. Thall, Aron; Pathan, Nuzhat; V. Schmidt, Emmett; Q.M. Chow, Laura

doi:10.1158/1078-0432.ccr-17-1243

Public

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Published in Clinical Cancer Research • Jun 20, 2017

Authors:

Anthony W. Tolcher

Mario Sznol

Siwen Hu‐Lieskovan

Abstract

Abstract Purpose: This phase Ib study (NCT02179918) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of utomilumab, a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137 in combination with the humanized, PD-1–blocking IgG4 mAb pembrolizumab ...

Subject

Pembrolizumab

CD137

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!